Nuritas Published Peer-Reviewed PeptiSleep™ Sleep Study in Sleep Medicine: X

Peer-reviewed study pairs clinically validated questionnaires with Oura Ring biometrics, offering a solid blueprint for how functional ingredients will be substantiated in a wearable-first world

DUBLIN, Ireland – [August 11] – Nuritas, the AI-driven biotech company that discovers and clinically validates bioactive peptides from natural sources, today announced the publication of a peer-reviewed pilot study on its sleep ingredient PeptiSleep™ in Sleep Medicine: X, the open-access companion journal to Sleep Medicine, published by Elsevier.

The study, “Effects of PeptiSleep™ on Sleep Modification and Biometrics in Adults with Sleep Impairment: A Randomised, Placebo-Controlled Pilot Study,” is notable not only for its findings on PeptiSleep™ itself, but for how it was measured: alongside the clinically validated Leeds Sleep Evaluation Questionnaire (LSEQ), every participant wore an Oura Ring throughout the trial to passively track over 15 biometrics including heart rate variability, sleep architecture, and sleep latency in real-world, at-home conditions, not a sleep lab.

For Nuritas, that pairing is the headline. As consumer wearables reach research-grade accuracy, the company believes they are becoming essential infrastructure for substantiating the next generation of functional ingredients, replacing single-point-in-time lab visits with continuous, objective, real-world data.

“Sleep research has advanced enormously over the last twenty years. While isolated nights of polysomnography, wired up to monitors in a strange bed are still considered the gold standard AI is transforming our ability to make connections and interpret complex data. The next big paradigm shift will be the widespread adaptation of wearable technology. Continuous, non-invasive, passive monitoring means we can assess sleep biometrics when a participant is in their own bed, night after night, not when in a lab away from home comforts. But technology without education is just noise. Sleep is complex, and stress affects some people far more than others, so a number on a screen doesn’t mean much on its own. What matters is using clinically validated measures alongside that data to spot bad habits, understand your own patterns, build better sleep hygiene, and, if you choose to use a supplement, actually see for yourself whether it’s working for you. Our approach to hybrid-type clinical designs provides the scientific backing for novel ingredients in a way that will translate when you’re at home.” Dr.Niamh Maire Mohan, PhD, Head of Clinical Trials at Nuritas

Study design and findings

The 8-week (56-day), randomised, placebo-controlled, parallel-design pilot enrolled 26 adults (aged 18–65) with self-reported sleep impairment. Participants received either PeptiSleep™, a rice protein hydrolysate containing AI-discovered bioactive peptides derived from brown rice, or a placebo.

Key findings:

• First AI-discovered sleep ingredient tested in a placebo-controlled trial: PeptiSleep™, a rice protein hydrolysate identified using Nuritas’ AI discovery platform, is the first in silico-predicted plant peptide ingredient to be assessed in a placebo-controlled sleep trial.
• Subjective and objective data on sleep quality were consistent:PeptiSleep™ users reported improvements across all four domains of the LSEQ (ease of getting to sleep, quality of sleep, behavior following wakefulness, and alertness on waking), with nominally significant differences versus placebo in the sleep initiation(p=0.050) and sleep maintanance (p=0.036) domains. This was supported by trends in exploratory objective data collected using the Oura wearables showing higher heart rate variability, lower nocturnal heart rate, and deep sleep, signals of more restorative sleep.
• Mood improved alongside sleep, with a strong safety profile: The PeptiSleep group showed a nominally significant reduction in total mood disturbance (p=0.029) versus placebo by day 56, and the supplement was well tolerated over the 8-week study with no clinically significant safety findings
• Findings from the exploratory pilot with dynamic trial design warrants follow-on trial: As a placebo-controlled pilot study (n=26), these findings are exploratory, directional, and hypothesis-generating rather than confirmatory. That said, the consistency across independent measures, subjective questionnaires, mood scales, and passive wearable biometrics, gives Nuritas a strong signal to build on. The team is now planning larger, follow-on trials to build on these results

“Sleep research has always had a data problem. Questionnaires tell you how someone felt about their sleep, but not what actually happened in their body while they were sleeping,” said Dr. Nora K. , Founder and CEO of Nuritas. “Putting an Oura Ring on every participant let us see both sides of the story in the environment where sleep happens, in someone’s own bed. That’s the model we believe the entire industry is moving toward, and we wanted PeptiSleep™ to lead the way.”

Why this matters for precision nutrition

The publication lands as brands and researchers increasingly look to wearables such as rings, patches, and continuous monitors, to move nutrition science out of the lab and into daily life. Nuritas argues that ingredient companies willing to build their evidence base this way, combining validated questionnaires with continuous biometric data, will set the standard other functional ingredient developers are measured against. PeptiSleep™ is available as a powder ingredient suited to capsules, tablets, gummies, gels, chews, ready-to-drink beverages, and health shots, and can be used alongside or in place of ingredients such as melatonin.

The full study is available open access via Sleep Medicine: X (Elsevier/ScienceDirect).

About Nuritas

Nuritas is a global biotech firm using artificial intelligence to discover clinically validated peptides from nature. Its proprietary Magnifier NπΦ platform rapidly analyses proteins to identify peptides with the potential to support human health, enabling partners to bring scientifically substantiated innovation to market faster. Founded in 2014 by mathematician and scientist Dr Nora Khaldi, Nuritas is headquartered in Dublin, Ireland, with its North American headquarters in Connecticut, USA. Its partners include GNC, The Vitamin Shoppe, Mars, Nestlé, L’Oréal and Givaudan.

Media Contact

Gabriela Leme – Brand Specialist at Nuritas

[email protected]